InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.70
(
0.01%
)
US TECH 100
19,450.80
(
-0.10%
)
Dow Jones
42,205.80
(
-0.25%
)
Brent Oil
72.37
(
0.92%
)
Bitcoin
63,573.15
(
-3.13%
)
Post# of 253253
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120510
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 85605

Friday, 10/30/2009 7:42:59 PM

Friday, October 30, 2009 7:42:59 PM

Post# of 253253

A big difference is IDX899 was an HIV drug and nvs has no presence in hiv.

NVS doesn’t have any presence in HCV either—unless you count Albuferon.

If NVS has concluded that Albuferon will be a commercial dud, its economic impetus for in-licensing other antiviral drugs goes down significantly.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up